Top-down MS for rapid methionine oxidation site assignment in filgrastim

AbstractProtein therapeutics have emerged as a major new class of pharmaceuticals. One important shelf-life-limiting factor of biopharmaceuticals is methionine oxidation, and therefore, it is important that analytical methods are able to thoroughly characterize all possible oxidized variants. Here, we present a fast and sensitive method to perform online methionine oxidation site assignment using granulocyte colony-stimulating factor (filgrastim) as a model. The method is based on top-down MS using the all-ion fragmentation mode of the Exactive benchtop mass spectrometer. Conditions that provide information on the intact mass of the protein as well as on fragment ions that allow unambiguous site assignment of methionine oxidation in filgrastim variants as low as 0.12 % of total peak area in a chromatographic time scale were identified. Using this method, we performed methionine oxidation site assignment in H2O2-stressed filgrastim and in filgrastim which was stored at intended conditions, respectively. We show that the relative abundance of oxidation species observed in filgrastim stored under intended conditions differs strikingly from the oxidized species observed after H2O2 stress. Additionally, we report an oxidized filgrastim variant that has not been previously described in the literature. FigureA top-down approach on an Exactive benchtop mass spectrometer in all-ion fragmentation mode is a highly attractive alternative to the traditional approach of isolation/bottom-up analysis for methionine oxidation site assignement in biopharmaceuticals. With a sensitivity as low as 0.12 % of total peak area and a throughput of about one sample per hour, the method is highly suitable for a thorough characterization of oxidized methionine residues

[1]  Leonid Zamdborg,et al.  The emerging process of Top Down mass spectrometry for protein analysis: biomarkers, protein-therapeutics, and achieving high throughput. , 2010, Molecular bioSystems.

[2]  M. Mann,et al.  Proteomics on an Orbitrap Benchtop Mass Spectrometer Using All-ion Fragmentation , 2010, Molecular & Cellular Proteomics.

[3]  F. Sörgel,et al.  Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with its Reference Product , 2010, BioDrugs.

[4]  N. Kearney,et al.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.

[5]  N. Kunishima,et al.  Atomic structure of the GCSF–receptor complex showing a new cytokine–receptor recognition scheme , 1999, Nature.

[6]  M. Aapro,et al.  Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[7]  V. Katta,et al.  Structural characterization of intact antibodies by high-resolution LTQ Orbitrap mass spectrometry. , 2009, Journal of mass spectrometry : JMS.

[8]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[9]  Zhongqi Zhang,et al.  Characterization of variable regions of monoclonal antibodies by top-down mass spectrometry. , 2007, Analytical chemistry.

[10]  Bernhardt L. Trout,et al.  Effects of Antioxidants on the Hydrogen Peroxide-Mediated Oxidation of Methionine Residues in Granulocyte Colony-Stimulating Factor and Human Parathyroid Hormone Fragment 13-34 , 2004, Pharmaceutical Research.

[11]  J. Nemunaitis A Comparative Review of Colony-Stimulating Factors , 1997, Drugs.

[12]  Scott A McLuckey,et al.  'Top down' protein characterization via tandem mass spectrometry. , 2002, Journal of mass spectrometry : JMS.

[13]  Richard D. LeDuc,et al.  Mapping Intact Protein Isoforms in Discovery Mode Using Top Down Proteomics , 2011, Nature.

[14]  L. F. Waanders,et al.  Top-down Protein Sequencing and MS3 on a Hybrid Linear Quadrupole Ion Trap-Orbitrap Mass Spectrometer*S , 2006, Molecular & Cellular Proteomics.

[15]  Peter Oefner,et al.  BIOANALYSIS , 2008, Electrophoresis.

[16]  Bernhardt L Trout,et al.  Molecular dynamics simulations and oxidation rates of methionine residues of granulocyte colony-stimulating factor at different pH values. , 2004, Biochemistry.

[17]  Bernhardt L Trout,et al.  Comparative oxidation studies of methionine residues reflect a structural effect on chemical kinetics in rhG-CSF. , 2006, Biochemistry.

[18]  M. Mccamish,et al.  The State of the Art in the Development of Biosimilars , 2012, Clinical pharmacology and therapeutics.

[19]  P. Bondarenko,et al.  Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer , 2009, Journal of the American Society for Mass Spectrometry.

[20]  David C. Dale,et al.  Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients , 2002, Drugs.

[21]  D. Figeys,et al.  Advancements in top-down proteomics. , 2012, Analytical chemistry.

[22]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[23]  J. Beijnen,et al.  Oxidation of recombinant methionyl human granulocyte colony stimulating factor. , 1998, Journal of pharmaceutical and biomedical analysis.

[24]  B. Warrack,et al.  Characterization of protein therapeutics by mass spectrometry: recent developments and future directions. , 2011, Drug discovery today.

[25]  M. Macht Mass spectrometric top-down analysis of proteins. , 2009, Bioanalysis.

[26]  D Eisenberg,et al.  The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Škrlin,et al.  Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities. , 2010, Journal of pharmaceutical and biomedical analysis.

[28]  E. Veltri,et al.  Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. , 2012, Future oncology.

[29]  I. Campbell,et al.  Secondary structure and backbone dynamics of human granulocyte colony-stimulating factor in solution. , 1994, Biochemistry.

[30]  Daniel I. C. Wang,et al.  Effects of Excipients on the Hydrogen Peroxide-Induced Oxidation of Methionine Residues in Granulocyte Colony-Stimulating Factor , 2004, Pharmaceutical Research.

[31]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[32]  D. Metcalf Granulocyte-macrophage colony-stimulating factors , 1985, Cell.

[33]  Fred W. McLafferty,et al.  Top-down identification and characterization of biomolecules by mass spectrometry , 2008, Journal of the American Society for Mass Spectrometry.

[34]  G Shimamoto,et al.  Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. , 1999, Archives of biochemistry and biophysics.

[35]  P. Gascón Presently available biosimilars in hematology-oncology: G-CSF , 2012, Targeted Oncology.

[36]  Matthew T. Mazur,et al.  A Platform for Characterizing Therapeutic Monoclonal Antibody Breakdown Products by 2D Chromatography and Top-Down Mass Spectrometry , 2012, The AAPS Journal.